155 related articles for article (PubMed ID: 19517469)
1. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
Samanta AK; Huang HJ; Le XF; Mao W; Lu KH; Bast RC; Liao WS
Cancer; 2009 Sep; 115(17):3897-908. PubMed ID: 19517469
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.
Samanta AK; Huang HJ; Bast RC; Liao WS
J Biol Chem; 2004 Feb; 279(9):7576-83. PubMed ID: 14662759
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk between the TNF and IGF pathways enhances NF-κB activation and signaling in cancer cells.
Li S; Pinard M; Wang Y; Yang L; Lin R; Hiscott J; Su B; Brodt P
Growth Horm IGF Res; 2015 Oct; 25(5):253-61. PubMed ID: 26239406
[TBL] [Abstract][Full Text] [Related]
4. LncRNA-MALAT1 promotes tumorogenesis of infantile hemangioma by competitively binding miR-424 to stimulate MEKK3/NF-κB pathway.
Li MM; Dong CX; Sun B; Lei HZ; Wang YL; Gong YB; Sun LL; Sun ZW
Life Sci; 2019 Dec; 239():116946. PubMed ID: 31610202
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
[TBL] [Abstract][Full Text] [Related]
6. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
[TBL] [Abstract][Full Text] [Related]
7. The expression and role of MEKK3 in renal clear cell carcinoma.
Lu H; Cao X; Chen Q; Chen L; Chen L; Gan M
Anat Rec (Hoboken); 2015 Apr; 298(4):727-34. PubMed ID: 25388155
[TBL] [Abstract][Full Text] [Related]
8. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.
Yang G; Rosen DG; Liu G; Yang F; Guo X; Xiao X; Xue F; Mercado-Uribe I; Huang J; Lin SH; Mills GB; Liu J
Clin Cancer Res; 2010 Aug; 16(15):3875-86. PubMed ID: 20505188
[TBL] [Abstract][Full Text] [Related]
9. Restoration of NF-kappaB activation by tumor necrosis factor alpha receptor complex-targeted MEKK3 in receptor-interacting protein-deficient cells.
Blonska M; You Y; Geleziunas R; Lin X
Mol Cell Biol; 2004 Dec; 24(24):10757-65. PubMed ID: 15572679
[TBL] [Abstract][Full Text] [Related]
10. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells.
Gründker C; Schulz K; Günthert AR; Emons G
J Clin Endocrinol Metab; 2000 Oct; 85(10):3815-20. PubMed ID: 11061544
[TBL] [Abstract][Full Text] [Related]
11. Protein phosphatase 2A acts as a mitogen-activated protein kinase kinase kinase 3 (MEKK3) phosphatase to inhibit lysophosphatidic acid-induced IkappaB kinase beta/nuclear factor-kappaB activation.
Sun W; Wang H; Zhao X; Yu Y; Fan Y; Wang H; Wang X; Lu X; Zhang G; Fu S; Yang J
J Biol Chem; 2010 Jul; 285(28):21341-8. PubMed ID: 20448038
[TBL] [Abstract][Full Text] [Related]
12. TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation.
Blonska M; Shambharkar PB; Kobayashi M; Zhang D; Sakurai H; Su B; Lin X
J Biol Chem; 2005 Dec; 280(52):43056-63. PubMed ID: 16260783
[TBL] [Abstract][Full Text] [Related]
13. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.
Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of Thr-516 and Ser-520 in the kinase activation loop of MEKK3 is required for lysophosphatidic acid-mediated optimal IkappaB kinase beta (IKKbeta)/nuclear factor-kappaB (NF-kappaB) activation.
Sun W; Ge N; Yu Y; Burlingame S; Li X; Zhang M; Ye S; Fu S; Yang J
J Biol Chem; 2010 Mar; 285(11):7911-8. PubMed ID: 20068038
[TBL] [Abstract][Full Text] [Related]
15. RNAi silencing of the MEKK3 gene promotes TRAIL-induced apoptosis in MCF-7 cells and suppresses the transcriptional activity of NF-κB.
Guo SY; Liu SG; Liu L; Zhou XJ; Gu Y
Oncol Rep; 2012 Feb; 27(2):441-6. PubMed ID: 22020406
[TBL] [Abstract][Full Text] [Related]
16. Regulation of NF-kappaB-dependent T cell activation and development by MEKK3.
Shinohara H; Yamasaki S; Maeda S; Saito T; Kurosaki T
Int Immunol; 2009 Apr; 21(4):393-401. PubMed ID: 19223432
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB activation by the chemopreventive dithiolethione oltipraz is exerted through stimulation of MEKK3 signaling.
Nho CW; O'Dwyer PJ
J Biol Chem; 2004 Jun; 279(25):26019-27. PubMed ID: 15047705
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of serine 526 is required for MEKK3 activity, and association with 14-3-3 blocks dephosphorylation.
Fritz A; Brayer KJ; McCormick N; Adams DG; Wadzinski BE; Vaillancourt RR
J Biol Chem; 2006 Mar; 281(10):6236-45. PubMed ID: 16407301
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
Cheng JC; Auersperg N; Leung PC
Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
